Determination of Risk Factors Associated with the Failure of 12 Weeks of Direct-Acting Antiviral Therapy in Patients with Hepatitis C: A Prospective Study
Table 1
Comparison of clinical characteristics between group 0 () and group 1 ().
Characteristic
Group 0 ()
Group 1 ()
2
OR (95% CI)
value
Age, years,
0.01
0.732
Sex (male), (%)
157 (65.69)
68 (71.58)
1.32 (0.79, 2.24)
0.366
BMI,
0.01
0.686
Cirrhosis (Y/N), (%)
21 (8.79)
53 (55.79)
12.91 (7.15, 24.09)
0.001
Comorbidity
Diabetes, (%)
24 (10.04)
7 (7.37)
0.73 (0.28, 1.68)
0.535
Hypertension, (%)
14 (5.86)
8 (8.42)
1.49 (0.57, 3.64)
0.464
Ulcer, (%)
22 (9.21)
16 (16.84)
2 (0.98, 4)
0.057
HBV-HCV coinfection, (%)
5 (2.09)
55 (57.89)
61.49 (25.24, 187.94)
0.001
Malignancy (not including HCC)
8 (3.35)
3 (3.16)
0.98 (0.2, 3.53)
1
Drug regimen
SOF/LDV, (%)
155 (64.85)
66 (69.47)
1.24 (0.75, 2.08)
0.445
SOF/VEL, (%)
83 (34.73)
30 (31.58)
0.87 (0.52, 1.44)
0.611
Reach RVR, (%)
118 (49.37)
5 (5.26)
0.06 (0.02, 0.14)
0.001
FIB-4 score,
0.43
0.001
Baseline AST (U/L),
0.20
0.001
Baseline ALP (U/L),
0.22
0.001
Baseline total bilirubin (mg/dl),
0.01
0.368
Baseline serum creatinine, (μmol/L),
0.01
0.154
Baseline GFR (mL/min), mean ± SD
0.01
0.896
Baseline hemoglobin (g/L), mean ± SD
0.11
0.001
Baseline viral load log10 IU/ml,
0.10
0.001
Viral C genotype
Genotype 1, (%)
48 (20.08)
74 (77.89)
13.82 (7.86, 25.2)
0.001
Genotype 2, (%)
25 (10.46)
9 (9.47)
0.91 (0.39, 1.97)
1
Genotype 3, (%)
17 (7.11)
5 (5.26)
0.75 (0.24, 1.96)
0.632
Genotype 6, (%)
149 (62.34)
7 (7.37)
0.05 (0.02, 0.11)
0.001
BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; RVR, rapid virological response; LDV/SOF, ledipasvir/sofosbuvir; VEL/SOF: sofosbuvir/velpatasvir; AST: aspartate aminotransferase; ALT: alanine transaminase; FIB-4: fibrosis index based on four factors; GFR: glomerular filtration rate.